This is a past event. Registration is closed. View other WuXi AppTec events.

China Renaissance Workshop

13:30-17:00 March 5th, 2019 | B1 Floor St.Regis Hotel


Part I: China Renaissance's Outlook on Healthcare Capital Market

Review of 2018 Healthcare Primary Market

Rachel Yu, Managing Director of China Renaissance

Deep dive of healthcare private placement market with big picture and real data


Glance at Global Capital Market

Kevin Xie, Managing Director of China Renaissance

As for the future of global healthcare capital market, the only certainty is uncertainty. As your long-term capital market partner, we would like to share our point of view with you.


Science and Technology Innovation Board, A New Option for Biotech?

Hongwei Qi, Executive General Manager of Huajing Securities

Which kind of company can literally get benefit from the new board as new exit pathway, and are we approaching to NASDAQ?


Opportunities in Healthcare Industry under Superpower Dispute

Glenn Hassan, Director of China Renaissance

As Sino-US relationship is becoming complicated, what is potential impact on global healthcare innovation and collaboration?


Tale of Hong Kong IPO

Joe Lai, Managing Director of China Renaissance

Real story and insights behind Hong Kong IPOs of Biotech companies


Part II Panel Discussion: Surviving from 'Financing Winter'


How could a biotech/healthcare company seize the strategic opportunities? How to valuate the company and complete a fair and quick financing deal? How to create a win-win situation for both founders and investors?


Nancy Chang, Chairman and CEO of Ansun BioPharma

Jonathan Zhao, Executive Chairman of Transcenta Holding

Chenbing Wu, Founder and CEO of EpimAb Biotherapeutics

Yaolin Wang, Founder and CEO of InventisBio

Dongmei Ji, Founding Managing Partner and President of GP Healthcare Capital

Kexiang Zhou, Managing Director of CMBI


More from I-mab, Ascentage, OPM Biosciences, Kintor, Ark Biosciences, JD and Baidu are expected

China Renaissance Group

China Renaissance Group ("CR Group") is a leading financial institution that combines private placement advisory, M&A advisory, securities underwriting, research, sales and trading, investment management and other financial services. Providing one-stop financial services across mainland China, Hong Kong and the United States, CR Group operates a competitive and unique international network that connects China's capital markets with the rest of the world, serving new economy entrepreneurs and investors globally.


CR Group has offices in Beijing, Shanghai, Hong Kong and New York, with approximately 600 employees. As of March 31, 2018, we had advised on approximately 700 transactions worth over US$100 billion since our inception, and we had AUM of approximately US$4.1 billion in new economy investments.


CR Group's subsidiary Huajing Securities is one of the first securities firms set up in accordance with 10th Supplementary Agreement of "Mainland and Hong Kong Closer Economic Partnership Arrangement (CEPA)". Since its establishment, Huajing Securities has assembled strong investment banking, fixed income, asset management, wealth management, securities brokerage, and research teams to serve existing and new clients.